SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 10, 2012
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|(Commission File Number)||
|2 Snunit Street||20100|
|Science Park, POB 455|
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code +972-4-988-9488
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 7.01. Regulation FD Disclosure
On May 10, 2012, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that senior management will present at three upcoming conferences, as follows:
The Oppenheimer 13th Annual Israeli Conference on Sunday, May 13, 2012 at 1:00 PM IDT. The conference is being held at the David Intercontinental Hotel, Tel-Aviv, Israel.
The TASE & NASDAQ OMX 5th Annual Investor Conference on Thursday, May 17, 2012 at 11:00 AM EDT. The conference will be held at the NASDAQ MarketSite, New York, NY.
The ILSI-Biomed 2012 Conference on Monday, May 21, 2012 at 12:30 PM IDT. The ILSI-Biomed 2012 Conference is being held at the David Intercontinental Hotel, Tel-Aviv, Israel, May 21-23, 2012.
A copy of the press release is furnished as Exhibit 99.1.
The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
|99.1||Press release, dated May 10, 2012.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|PROTALIX BIOTHERAPEUTICS, INC.|
|Date: May 10, 2012||By:||/s/ David Aviezer|
|David Aviezer, Ph.D. |
Chief Executive Officer
Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences
CARMIEL, Israel, May 10, 2012 /GlobeNewswire /Protalix BioTherapeutics,
Inc. (NYSE-AMEX:PLX, TASE:PLX), today announced that senior management will present at three upcoming conferences.
Details regarding the conferences are as follows:
Oppenheimer 13th Annual Israeli Conference
Sunday, May 13, 2012 at 1:00 PM IDT
David Intercontinental Hotel, Tel-Aviv, Israel
TASE & NASDAQ OMX 5th Annual Investor
Thursday, May 17, 2012 at 11:00 AM EDT
NASDAQ MarketSite, New York, NY
ILSI-Biomed 2012 Conference
Monday, May 21, 2012 at 12:30 PM IDT
David Intercontinental Hotel, Tel-Aviv, Israel
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first approved product manufactured by ProCellEx, ELELYSO™ (taliglucerase alfa), was approved for marketing by the U.S. Food and Drug Administration on May 1, 2012 and is partnered with Pfizer for worldwide development and commercialization, excluding Israel, where Protalix retains full rights. Marketing applications for taliglucerase alfa have been filed in Europe, Israel, Brazil and Australia. Protalix's development pipeline also includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant human acetylcholinesterase in development for several therapeutic and prophylactic indications, a biodefense program and an organophosphate-based pesticide treatment program; an orally-delivered glucocerebrosidase enzyme that is naturally encased in carrot cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel(R)) for the treatment of certain immune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; and others.
Forward Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms "anticipate," "believe," "estimate," "expect" and "intend" and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. The statements in this release are valid only as of the date hereof and we disclaim any obligation to update this information.
The Trout Group, LLC
Jennifer Conrad or Kari Watson
MacDougall Biomedical Communications